Tag: GlobeNewswire

— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies. —

MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of chronic diseases, including neurofibromatosis type 1 (NF1)-associated neurofibromas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a randomized, placebo-controlled Phase 2 clinical trial for PAS-004 in patients with NF1 associated cutaneous neurofibromas (cNF). The Phase 2 study will be conducted under an active IND overseen by the FDA Division of Dermatology and Dentistry (DDD).

“FDA clearance of our IND for PAS-004 in cutaneous neurofibromas is an important milestone for Pasithea and a significant step forward for people living with NF1 who have cNFs,” said Kartik Krishnan, MD, PhD, Chief Medical Officer of Pasithea. “Cutaneous neurofibromas are among the most visible and burdensome manifestations of NF1, and there are currently no approved systemic therapies for them. PAS-004 is designed to address this unmet need as a once-daily oral MEK inhibitor whose long half-life and flat pharmacokinetic profile may support chronic dosing.”

“We are pleased to expand the clinical development of PAS-004 into NF1-associated cNF, the second indication for which we intend to seek regulatory approval. PAS-004 has the potential to become the first FDA-approved systemic treatment for NF1-associated cNF, addressing a significant unmet medical need and what we believe represents a multibillion-dollar market opportunity,” said Dr. Tiago Reis Marques, MD, PhD, CEO of Pasithea. “PAS-004 is intended for the more than 80,000 NF1 patients in the United States estimated to have moderate to severe cNF disease burden.”

Pasithea supported its IND with nonclinical safety, clinical safety, tolerability and pharmacokinetic data and early signals of treatment response emerging from its ongoing Phase 1/1b study in adults with NF1-associated plexiform neurofibromas and its ongoing Phase 1 study in adults with advanced cancer.

With the IND now in effect, Pasithea may proceed with clinical development of PAS-004 in patients with NF1-cNFs in the United States.

About Cutaneous Neurofibromas

NF1-associated cutaneous neurofibromas (cNF) are benign tumors that grow in or just beneath the skin at virtually any location in the body and are a hallmark of NF1 It is a serious condition and associated with significant morbidity that can have substantial impact on day-to-day functioning, leading patients to rate this as the most significant burden of NF1 despite other potentially life-threatening complications. cNF typically begin to appear in adolescence, generally increase in number and volume with age. The number of cNF on an individual patient can range from a few to tens of thousands. Although malignant transformation does not occur with NF1-associated cNF, cNF are present in over 95% of individuals with NF1 and have a significant negative impact both physically, with disfigurement, and on health-related quality of life (QoL). A greater cNF burden, particularly volume and number of cNF and facial involvement, are associated with poorer health-related QoL. Patients have rated cutaneous manifestations of NF1 as the most significant burden of NF1 largely owing to cNF-associated disfigurement despite other potentially life-threatening complications. In a Patient Listening Session organized by the Children’s Tumor Foundation (CTF), four of the six representatives who were selected to collectively represent the NF1 community described how the appearance of the cNF and associated stigma consistently interferes with their activities of daily living, including being denied employment opportunities, harassed and in fear of being out in public. Current management relies largely on procedural approaches such as surgical excision, electrodesiccation, or laser therapy. There are no FDA approved therapies approved for the treatment of NF1-associated cNF.

About Pasithea Therapeutics Corp.

Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s Investigational New Drug (IND) application for PAS-004 in cutaneous neurofibroma (cNF), the Company’s plans for and the design, timing, size, enrollment, and conduct of a Phase 2 clinical trial of PAS-004 in patients with NF1-associated cNF, the potential of PAS-004 as a treatment for cNF, the unmet medical need in cNF, the Company’s clinical data from its Phase 1 dose-escalation study of PAS-004 in advanced solid tumors, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks related to the initiation, design, timing, enrollment, and conduct of clinical trials and interactions with regulatory authorities, and risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Contact

Company Contact:
Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

BOSTON and SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management will participate in two upcoming investor conferences.

Stifel 2026 Healthcare Conference (New York City, NY)
Fireside chat on Wednesday, November 11, 2026, at 1:20 – 1:50 p.m. ET.

Jefferies Global Healthcare Conference (London, UK)
Company presentation followed by fireside chat on Monday, November 16, 2026, at 5:00 – 5:25 p.m. GMT / 12:00 – 12:25 p.m. ET.

Live webcasts and replays will be available in the Investors section of the Company’s website at www.rapportrx.com.https://investors.rapportrx.com/.

About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The Company’s founders made pioneering discoveries related to the function of receptor associated proteins (“RAPs”) in the brain, which form the basis of Rapport’s RAP technology platform. The platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, which is designed to achieve neuroanatomical specificity through selective targeting of a RAP expressed only in discrete regions of the brain. The Company’s late-stage programs include RAP-219 in epilepsy, including focal onset seizures and primary generalized tonic-clonic seizures, and in bipolar mania. The Company is also advancing additional discovery and preclinical programs leveraging its platform, including in chronic pain and migraine and in hearing and vestibular disorders.

CONTACT: Investor Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
investors@rapportrx.com

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:

• Guggenheim 3rd Annual Healthcare Innovation Conference
  Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ET
  Location: Boston, MA
• Stifel Healthcare Conference
  Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m. ET
  Location: New York, NY
• UBS Global Biopharma Conference
  Fireside Chat: Monday, November 16, 2026 at 12:00 p.m. GMT
  Location: London, UK
• Jefferies Global Healthcare Conference
  Fireside Chat: Tuesday, November 17, 2026 at 10:30 a.m. GMT
  Location: London, UK

Members of the Jade management team will host one-on-one investor meetings during the conferences.

A live webcast of each of the fireside chats will be available on the Events page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Jade Biosciences Contact

Zane Goodwin
IR@JadeBiosciences.com
Media@JadeBiosciences.com

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at Guggenheim’s 3^rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 8:00 AM EST.

The live webcast will be available under the “Events & Presentations” tab on the “Investors” page of the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer. Using an approach that focuses on genetic vulnerabilities in cancer, Tango Therapeutics is pursuing PRMT5-targeted therapies designed to address pancreatic and other forms of cancer while sparing healthy normal tissues. For more information, please visit www.tangotx.com.

Investors:
Elizabeth Hickin
ehickin@tangotx.com

Media:
1AB
Amanda Lazaro
amanda@1abmedia.com

• RISE Dispensary Mulberry expands access to medical cannabis for patients across Polk County with the opening of Green Thumb’s first RISE Dispensary in the county.
• RISE Dispensary Mulberry opens November 4 and will celebrate its grand opening event on December 4. Continuing with RISE’s new store opening tradition, a portion of profits from RISE Dispensary Mulberry’s grand opening will benefit local nonprofit Shepherd’s Lighthouse.

CHICAGO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis company with a portfolio of best-in-class brands and owner of RISE Dispensaries, today announced the opening of RISE Dispensary Mulberry, located at 6751 North Church Ave., Mulberry, FL 33860, on Wednesday, November 4, giving Polk County patients a new place to shop close to home. Marking RISE’s first location in Polk County, the new dispensary expands access to quality medical cannabis for patients in Mulberry, nearby Lakeland and surrounding communities, while strengthening Green Thumb’s growing presence across Central Florida.

With the addition of Mulberry, RISE now operates 27 dispensaries across Florida and more than 120 nationwide. The new location joins RISE Dispensaries in Brandon, Tampa, Sun City and Orlando in serving Central Florida’s medical cannabis patients.

“Opening our first RISE Dispensary in Polk County is an exciting milestone as we continue to expand access to quality cannabis across Florida. From RYTHM’s premium flower, rosin, and full-spectrum vapes to Dogwalkers pre-rolls, Doctor Solomon’s tinctures and topicals, and Beboe edibles, the menu at RISE Dispensary Mulberry is built around a product set that resonates with Florida patients,” said Green Thumb President Anthony Georgiadis. “We’re proud to expand access to quality medical cannabis and to invest in our people and the organizations that make Mulberry special. Through our First Day Profits program, we look forward to continuing to invest in the local nonprofit, Shepherd’s Lighthouse.”

RISE Dispensary Mulberry will offer patients a diverse selection of best-in-class, Florida-grown products, including RYTHM premium flower, full-spectrum vapes and concentrates, Dogwalkers pre-rolls, Good Green flower, &Shine flower and edibles, RISE flower and pre-rolls, Phat Panda flower and pre-rolls, Beboe edibles, and Doctor Solomon’s tinctures, RSO, and topicals. Many of these products are cultivated and produced from seed-to-sale at the Green Thumb Industries facility in Ocala, Florida. Patients can also have the same selection delivered to their homes for convenient, comfortable access.

Continuing RISE Dispensary’s tradition of giving back to each community it serves, profits from our Mulberry grand opening event will benefit Shepherd’s Lighthouse, building the partnership established with the opening of RISE Dispensary Belleview. Shepherd’s Lighthouse provides transitional housing, life-skills development, employment resources and other essential services to help individuals and families build greater stability and independence. By directing a portion of opening profits to a local organization in each new store we open, RISE Dispensaries is investing directly into the communities its patients and team members call home. To learn more about Shepherd’s Lighthouse’s mission and work, please visit their website.

RISE Dispensary Mulberry will mark the occasion with a grand opening event on Friday, December 4 at 9:00 a.m., featuring exclusive patient deals and promotions, giveaways, music, refreshments from a local food truck, and more.

RISE Dispensary Mulberry will be open Monday through Saturday from 9:00 a.m. to 8:00 p.m. ET and Sunday from 11:00 a.m. to 6:00 p.m. ET. Home delivery is available Monday through Saturday from 10:00 a.m. to 6:00 p.m. ET and Sunday from 11:00 a.m. to 5:00 p.m. ET.

Green Thumb entered the Florida market in 2018 and operates two production facilities, in Ocala and Homestead, where it cultivates and produces its branded products. Beyond RISE Dispensary Mulberry, the Company has 26 other RISE Dispensaries in Florida, with locations in Belleview, Bonita Springs, Brandon, Cape Coral, Clearwater, Crystal River, Deerfield Beach, Dunnellon, Fruitland Park, Hallandale Beach, Jacksonville, Kendall, New Port Richey, Ocala on College Rd, Orlando on Good Homes Rd, Oviedo, Pinellas Park, Port Charlotte, Port Orange, Port St. Lucie, Sun City, Tallahassee on Mahan, Tallahassee on Tennessee, Tampa, Wesley Chapel, and West Palm Beach. Roll-thru pick-up and delivery services are offered at select RISE Dispensaries in Florida.

To learn more about RISE Dispensaries’ locations, product offerings, or other services, visit www.risecannabis.com.

About RISE Dispensaries
RISE Dispensaries is a national cannabis retailer on a mission to promote well-being through the power of cannabis. Founded by Chicago-based Green Thumb Industries, RISE Dispensaries bring patients and customers the best, hand-picked products at a great value — all while providing best-in-class service, such as home delivery, virtual pharmacist consultations and mobile pre-ordering (services vary by market). RISE offers premium, high-quality cannabis products in a welcoming environment, featuring Green Thumb’s award-winning family of brands such as &Shine, Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. Since opening its doors in 2015, RISE has grown its national footprint to 120+ retail locations across 14 U.S. markets and serves millions of patients and customers each year. More information is available at www.risecannabis.com.

Cautionary Note Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Green Thumb Industries Inc. and other matters. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Such statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those implied by such statements. Green Thumb Industries Inc. undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Investor Contact:
Andy Grossman
EVP, Capital Markets & Investor Relations
InvestorRelations@gtigrows.com
310-622-8257

Media Contact:
GTI Communications
media@gtigrows.com

This press release was published by a CLEAR® Verified individual.

Same-Restaurant Sales Growth of 1.0%
Total revenues increased 10.7%
Net income of $4.8 million and Adjusted EBITDA of $39.7 million
16 new System-wide restaurants opened in 11 states

BRADENTON, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended September 27, 2026 (“Q3 2026”).

“Our third-quarter performance is another encouraging proof point for the strength of First Watch. We delivered on our top-line plan, grew same-restaurant sales against our toughest comparison of the year and increased total revenue by 10.7%, all while opening 16 system-wide restaurants across 11 states,” said Chris Tomasso, CEO and President of First Watch. “Our teams continue to execute at a high level, driving Adjusted EBITDA growth ahead of our expectations and giving us the confidence to raise our full-year 2026 Adjusted EBITDA outlook to the high end of our previous guidance range.”

Third Quarter 2026 Highlights:

• Total revenues increased 10.7% to $349.9 million as compared to $316.0 million in the same period of 2025
• System-wide sales increased 10.9% to $391.2 million as compared to $352.7 million in the same period of 2025
• Same-Restaurant Sales Growth of 1.0%
• Same-Restaurant Traffic Growth of negative 1.9%
• Income from operations margin remained flat at 3.2% as compared to the same period of 2025
• Restaurant level operating profit margin* decreased to 19.4% as compared to 19.7% in the same period of 2025
• Net income increased to $4.8 million, or $0.08 per diluted share, from net income of $3.0 million, or $0.05 per diluted share, in the same period of 2025
• Adjusted EBITDA* increased to $39.7 million as compared to $34.1 million in the same period of 2025
• Opened 16 system-wide restaurants in 11 states resulting in a total of 681 system-wide restaurants (601 company-owned and 80 franchise-owned) across 33 states

___________________
* See Non-GAAP Financial Measures Reconciliations section below.

For additional financial information related to Q3 2026, refer to the Company’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2026, which can be accessed at https://investors.firstwatch.com in the Financials & Filings section.

Updated Outlook Fiscal Year 2026

Based upon third quarter results and current trends, the Company updated the following guidance metrics for the 52-week fiscal year ending December 27, 2026:

• Same-Restaurant Sales Growth of ~2.0%
• Total revenue growth of ~13.5%⁽¹⁾
• Adjusted EBITDA⁽²⁾ of ~$136.0 million⁽¹⁾
• 60 net new System-wide restaurants, including 2 company-owned restaurant closures (53 new company-owned restaurants and 9 new franchise-owned restaurants)
• Capital expenditures of ~$145.0 million invested primarily in new restaurant projects and planned remodels⁽³⁾

______________________
(1) includes net impact of approximately 1% in total revenue growth and approximately $2 million in Adjusted EBITDA associated with completed acquisitions.
(2) We have not reconciled guidance for Adjusted EBITDA to the corresponding GAAP financial measure because we do not provide guidance for the various reconciling items. We are unable to provide guidance for these reconciling items because we cannot determine their probable significance, as certain items are outside of our control and cannot be reasonably predicted due to the fact that these items could vary significantly from period to period. Accordingly, a reconciliation to the corresponding GAAP financial measure is not available without unreasonable effort.
(3) Does not include the capital outlays associated with the acquisition of franchise-owned restaurants.

Conference Call and Webcast
Chris Tomasso, Chief Executive Officer and President, and Ashlee Weisser, Chief Financial Officer, will host a conference call and webcast to discuss these financial results for Q3 2026 on November 3, 2026 at 8:00 AM ET.

Interested parties may listen to the conference call via any one of two options:

• Dial 201-389-0914, which will be answered by an operator
• Join the webcast at https://investors.firstwatch.com/news-and-events/events

The webcast will be archived shortly after the call has concluded.

Definitions

The following definitions apply to these terms as used in this release:

System-wide restaurants: the total number of restaurants, including all company-owned and franchise-owned restaurants.

System-wide sales: consists of restaurant sales from our company-owned restaurants and franchise-owned restaurants. We do not recognize the restaurant sales from our franchise-owned restaurants as revenue.

Same-restaurant sales growth: the percentage change in year-over-year restaurant sales (excluding gift card breakage) for the comparable restaurant base, which we define as the number of company-owned First Watch branded restaurants open for 18 months or longer as of the beginning of the fiscal year (“Comparable Restaurant Base”). For the thirteen and thirty-nine weeks ended September 27, 2026 and September 28, 2025, there were 454 restaurants and 381 restaurants, respectively, in our Comparable Restaurant Base. Measuring our same-restaurant sales growth allows management to evaluate the performance of our existing restaurant base. We believe this measure is useful for investors to provide a consistent comparison of restaurant sales results and trends across periods within our core, established restaurant base, unaffected by results of store openings, closings, and other transitional changes.

Same-restaurant traffic growth: the percentage change in year-over-year traffic counts using the Comparable Restaurant Base. Measuring our same-restaurant traffic growth allows management to evaluate the performance of our existing restaurant base. We believe this measure is useful for investors because same-restaurant traffic provides an indicator as to the development of our brand and the effectiveness of our marketing strategy.

Adjusted EBITDA: a non-GAAP measure, represents Net income (loss) before depreciation and amortization, interest expense, income taxes and items that we do not consider in our evaluation of ongoing core operating performance.

Adjusted EBITDA margin: a non-GAAP measure, represents Adjusted EBITDA as a percentage of total revenues.

Restaurant level operating profit: a non-GAAP measure, represents restaurant sales, less restaurant operating expenses, which include food and beverage costs, labor and other related expenses, other restaurant operating expenses, pre-opening expenses and occupancy expenses. Restaurant level operating profit excludes corporate-level expenses and other items that we do not consider in the evaluation of the ongoing core operating performance of our restaurants.

Restaurant level operating profit margin: a non-GAAP measure, represents Restaurant level operating profit as a percentage of restaurant sales.

About First Watch

First Watch is the leading Daytime Dining concept serving made-to-order breakfast, brunch and lunch using the freshest ingredients available. Guided by its “Follow the Sun” culinary philosophy, First Watch’s chef-driven menu rotates multiple times per year to feature the highest-quality flavors at their peak, offering elevated executions of classic favorites, fresh juices like the Kale Tonic, and fan favorites such as the Lemon Ricotta Pancakes, Quinoa Power Bowl and signature Million Dollar Bacon. For every kid’s meal served, First Watch proudly donates a portion to organizations and causes making a positive impact in our communities – raising millions to date. A recipient of many “Best Breakfast” and “Best Brunch” awards, First Watch was voted #1 Best Breakfast by Newsweek’s Readers’ Choice Awards 2025, and also named 2025 and 2024’s #1 Most Loved Workplace® in America by the Best Practice Institute – an accolade most recently featured in The Wall Street Journal – after appearing on the list in 2022 and 2023, as well. With a commitment to quality, hospitality and community, First Watch is redefining Daytime Dining across more than 680 restaurants in 33 states. For more information, visit www.firstwatch.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to known and unknown risks, uncertainties and other important factors that may cause actual results to be materially different from the statements made herein. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements can be identified by words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “outlook,” “potential,” “project,” “projection,” “plan,” “seek,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other similar expressions. Examples of forward-looking statements include, but are not limited to, statements we make regarding the outlook for our future business and financial performance and statements discussing our current expectations and projections relating to our financial position, results of operations, plans, objectives, future performance and business. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include:

• our vulnerability to changes in consumer preferences and economic conditions such as inflation and recession;
• our inability to successfully open new restaurants or establish new markets;
• our inability to effectively manage our growth;
• potential negative impacts on sales at our and our franchisees’ restaurants as a result of our opening new restaurants in existing markets;
• a decline in visitors to any of the retail centers, lifestyle centers, or entertainment centers where our restaurants are located;
• lower than expected same-restaurant sales growth;
• unsuccessful marketing programs and limited time new offerings;
• changes in the cost of food;
• unprofitability or closure of new restaurants or lower than previously experienced performance in existing restaurants;
• our inability to compete effectively for customers;
• our vulnerability to food safety and food-borne illness concerns;
• unsuccessful financial performance of our franchisees;
• our limited control over our franchisees’ operations;
• our inability to maintain good relationships with our franchisees and conflicts of interest with our franchisees;
• the geographic concentration of our system-wide restaurant base in the southeast portion of the United States;
• damage to our reputation and negative publicity;
• our inability or failure to recognize, respond to and effectively manage the accelerated impact of social media and artificial intelligence;
• our limited number of suppliers and distributors for several of our frequently used ingredients and shortages or disruptions in the supply or delivery of such ingredients;
• information technology system failures or breaches of our network security;
• our failure to comply with federal and state laws and regulations relating to privacy, data protection, advertising and consumer protection, or the expansion of current or the enactment of new laws or regulations relating to privacy, data protection, advertising and consumer protection;
• our potential liability with our gift cards under the property laws of some states;
• our failure to enforce and maintain our trademarks and protect our other intellectual property;
• litigation with respect to intellectual property assets;
• our dependence on our executive officers and certain other key employees;
• our inability to identify, hire, train and retain qualified individuals for our workforce;
• our failure to obtain or to properly verify the employment eligibility of our employees;
• our failure to maintain our corporate culture as we grow;
• unionization activities among our employees;
• employment and labor law proceedings;
• labor shortages or increased labor costs or health care costs;
• risks associated with leasing property subject to long-term and non-cancelable leases;
• risks related to our sale of alcoholic beverages;
• costly and complex compliance with federal, state and local laws, including trade and tax policies;
• changes in accounting principles applicable to us;
• our vulnerability to natural disasters, unusual weather conditions, pandemic outbreaks, political events, war and terrorism;
• our inability to secure additional capital to support business growth;
• our level of indebtedness;
• failure to comply with covenants under our credit facility; and
• uncertainty regarding the Russia and Ukraine war, war and unrest in the Middle East and the related impact on macroeconomic conditions, including inflation, as a result of such conflicts or other related events.

See Part I. Item 1A. “Risk Factors” in our Annual Report on Form 10-K as of and for the year ended December 28, 2025 (“2025 Form 10-K”) for a further description of these and other factors. For the reasons described above, we caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release and in our filings with the Securities and Exchange Commission (the “SEC”). Any forward-looking statement made by us in this press release speaks only as of the date hereof and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Relations Contact

Steven L. Marotta
941-500-1918
investors@firstwatch.com

Media Relations Contact

Jenni Glester
407-864-5823
jglester@firstwatch.com

Non-GAAP Financial Measures (Unaudited)

To supplement the consolidated financial statements, which are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), we use the following non-GAAP measures, which present operating results on an adjusted basis: (i) Adjusted EBITDA, (ii) Adjusted EBITDA margin, (iii) Restaurant level operating profit and (iv) Restaurant level operating profit margin. Our presentation of these non-GAAP measures includes isolating the effects of some items that are either nonrecurring in nature or have no meaningful correlation to our ongoing core operating performance. These supplemental measures of performance are not required by or presented in accordance with GAAP. Management believes these non-GAAP measures provide investors with additional visibility into our operations, facilitate analysis and comparisons of our ongoing business operations because they exclude items that may not be indicative of our ongoing operating performance, help to identify operational trends and allow for greater transparency with respect to key metrics used by Management in our financial and operational decision-making. Our non-GAAP measures may not be comparable to similarly titled measures used by other companies and have important limitations as analytical tools. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of our results as reported under GAAP as they may not provide a complete understanding of our performance. These non-GAAP measures should be reviewed in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Adjusted EBITDA and Adjusted EBITDA Margin

Management uses Adjusted EBITDA and Adjusted EBITDA margin (i) as factors in evaluating management’s performance when determining incentive compensation, (ii) to evaluate the Company’s operating results and the effectiveness of our business strategies and (iii) internally as benchmarks to compare the Company’s performance to that of its competitors.

Non-GAAP Financial Measures Reconciliations

Adjusted EBITDA and Adjusted EBITDA margin – The following table reconciles Net income and Net income margin, the most directly comparable GAAP measures to Adjusted EBITDA and Adjusted EBITDA margin, for the periods indicated:

	THIRTEEN WEEKS ENDED								THIRTY-NINE WEEKS ENDED
(in thousands)	SEPTEMBER 27, 2026				SEPTEMBER 28, 2025				SEPTEMBER 27, 2026				SEPTEMBER 28, 2025
Net income	$	4,787			$	2,991			$	4,441			$	4,268
Depreciation and amortization		22,700				19,662				65,935				54,355
Interest expense		4,933				4,567				14,603				11,904
Income tax expense		1,690				2,683				1,970				3,445
EBITDA		34,110				29,903				86,949				73,972
Strategic transition costs (1)		509				715				1,113				2,748
Stock-based compensation, net of amounts capitalized (2)		3,639				2,877				10,688				7,926
Delaware Voluntary Disclosure Agreement Program (3)		—				1				—				54
Transaction and restructuring expenses, net (4)		1,320				428				2,828				2,220
Impairments and loss on disposal of assets (5)		170				175				437				311
Adjusted EBITDA	$	39,748			$	34,099			$	102,015			$	87,231
Total revenues	$	349,861			$	316,022			$	1,035,492			$	906,149
Net income margin		1.4	%			0.9	%			0.4	%			0.5	%
Adjusted EBITDA margin		11.4	%			10.8	%			9.9	%			9.6	%
Additional information
Deferred rent (6)	$	(337	)		$	(141	)		$	(836	)		$	337

___________________________
(1) Represents costs related to process improvements and strategic initiatives. These costs are recorded within General and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income.
(2) Represents non-cash, stock-based compensation expense, net of amounts capitalized, which is recorded within General and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income.
(3) Represents professional service costs incurred in connection with the Delaware Voluntary Disclosure Agreement Program related to unclaimed or abandoned property. These costs are recorded in General and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income.
(4) Represents severance costs resulting from organizational optimization, costs incurred in connection with the acquisition of franchise-owned restaurants, non-recurring professional fees, secondary equity offering costs, costs related to restaurant closures and investor relations costs.
(5) Represents impairment charges and costs related to the disposal of assets due to retirements, replacements and restaurant closures.
(6) Represents the non-cash portion of straight-line rent recorded within both Occupancy expenses and General and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income.

Restaurant level operating profit and Restaurant level operating profit margin

Restaurant level operating profit and Restaurant level operating profit margin are not indicative of our overall results and, because they exclude corporate-level expenses, do not accrue directly to the benefit of our stockholders. We will continue to incur such expenses in the future. Restaurant level operating profit and Restaurant level operating profit margin are important measures we use to evaluate the performance and profitability of each operating restaurant, individually and in the aggregate and to make decisions regarding future spending and other operational decisions. We believe that Restaurant level operating profit and Restaurant level operating profit margin provide useful information about our operating results, identify operational trends and allow for transparency with respect to key metrics used by us in our financial and operational decision-making.

The following tables reconcile Income from operations and Income from operations margin, the most directly comparable GAAP financial measures, to Restaurant level operating profit and Restaurant level operating profit margin for the periods indicated:

	THIRTEEN WEEKS ENDED								THIRTY-NINE WEEKS ENDED
(in thousands)	SEPTEMBER 27, 2026				SEPTEMBER 28, 2025				SEPTEMBER 27, 2026				SEPTEMBER 28, 2025
Income from operations	$	11,048			$	10,050			$	20,174			$	18,476
Less: Franchise revenues		(3,139	)			(2,386	)			(9,141	)			(7,939	)
Add:
General and administrative expenses		35,244				33,746				113,916				97,150
Depreciation and amortization		22,700				19,662				65,935				54,355
Transaction and restructuring expenses, net(1)		1,320				428				2,828				2,220
Impairments and loss on disposal of assets(2)		170				175				437				311
Restaurant level operating profit	$	67,343			$	61,675			$	194,149			$	164,573
Restaurant sales	$	346,722			$	313,636			$	1,026,351			$	898,210
Income from operations margin		3.2	%			3.2	%			2.0	%			2.1	%
Restaurant level operating profit margin		19.4	%			19.7	%			18.9	%			18.3	%
Additional information
Deferred rent(3)	$	(353	)		$	(168	)		$	(883	)		$	211

____________________________
(1) Represents severance costs resulting from organizational optimization, costs incurred in connection with the acquisition of franchise-owned restaurants, non-recurring professional fees, secondary equity offering costs, costs related to restaurant closures and investor relations costs.
(2) Represents impairment charges and costs related to the disposal of assets due to retirements, replacements and restaurant closures.
(3) Represents the non-cash portion of straight-line rent recorded within Occupancy expenses on the Consolidated Statements of Operations and Comprehensive Income.

FIRST WATCH RESTAURANT GROUP, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) (Unaudited)
	THIRTEEN WEEKS ENDED								THIRTY-NINE WEEKS ENDED
	SEPTEMBER 27, 2026				SEPTEMBER 28, 2025				SEPTEMBER 27, 2026				SEPTEMBER 28, 2025
Revenues
Restaurant sales	$	346,722			$	313,636			$	1,026,351			$	898,210
Franchise revenues		3,139				2,386				9,141				7,939
Total revenues		349,861				316,022				1,035,492				906,149
Operating costs and expenses
Restaurant operating expenses (exclusive of depreciation and amortization shown below):
Food and beverage costs		77,402				69,730				234,305				208,355
Labor and other related expenses		112,962				102,387				339,294				300,451
Other restaurant operating expenses		56,048				50,140				163,509				141,002
Occupancy expenses		29,506				25,891				85,261				73,849
Pre-opening expenses		3,461				3,813				9,833				9,980
General and administrative expenses		35,244				33,746				113,916				97,150
Depreciation and amortization		22,700				19,662				65,935				54,355
Impairments and loss on disposal of assets		170				175				437				311
Transaction and restructuring expenses, net		1,320				428				2,828				2,220
Total operating costs and expenses		338,813				305,972				1,015,318				887,673
Income from operations		11,048				10,050				20,174				18,476
Interest expense		(4,933	)			(4,567	)			(14,603	)			(11,904	)
Other income, net		362				191				840				1,141
Income before income taxes		6,477				5,674				6,411				7,713
Income tax expense		(1,690	)			(2,683	)			(1,970	)			(3,445	)
Net income	$	4,787			$	2,991			$	4,441			$	4,268
Net income	$	4,787			$	2,991			$	4,441			$	4,268
Other comprehensive income (loss):
Unrealized gain (loss) on derivatives		1,331				88				2,381				(920	)
Income tax related to other comprehensive income (loss)		(330	)			(22	)			(590	)			229
Comprehensive income	$	5,788			$	3,057			$	6,232			$	3,577
Net income per common share – basic	$	0.08			$	0.05			$	0.07			$	0.07
Net income per common share – diluted	$	0.08			$	0.05			$	0.07			$	0.07
Weighted average number of common shares outstanding – basic		61,719,871				61,027,278				61,544,361				60,933,443
Weighted average number of common shares outstanding – diluted		62,550,856				62,834,080				62,600,196				62,798,962

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced its participation in Guggenheim’s 3^rd Annual Healthcare Innovations Conference being held at the Intercontinental Boston. Management will participate in a fireside chat on Tuesday, November 10, 2026, at 3:00 pm Eastern Time and will also participate in one-on-one investor meetings.

An audio webcast of the fireside chat can be accessed on the Events & Presentations page of the Investors section of BlossomHill’s website. An archived replay will be available for 90 days.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR^TM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit www.bhtherapeutics.com and follow us on LinkedIn and X.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

Envoy brings its on-site EV car-sharing amenity to the 321-unit Montage at Midtown residential community, offering residents access to Tesla Model 3 vehicles through its mobile app.

FORT MYERS, FL, Nov. 03, 2026 (GLOBE NEWSWIRE) —  Envoy, a provider of on-site electric vehicle car-sharing services and a wholly owned subsidiary of CID HoldCo, Inc., doing business as Dot Ai (Nasdaq: DAIC), (“Dot AI”), today announced its expansion into Southwest Florida with the launch of on-site EV car sharing at Montage at Midtown, a 321-unit residential community within Fort Myers’ $100 million Midtown redevelopment.

Developed by Catalyst Community Development and managed by ZRS Management, Montage at Midtown now offers residents access to two Tesla Model 3 vehicles through Envoy’s “Mobility as an Amenity®” platform, available to reserve by the hour or day through the Envoy Mobility app. The launch marks Envoy’s first location in Southwest Florida, extending its Florida footprint beyond Miami.

The service gives residents convenient access to an electric vehicle without the costs and responsibilities of owning an additional car. For multifamily developers and property managers, on-site EV car sharing offers a differentiated amenity that expands transportation options and introduces greater flexibility into residential amenity and mobility planning.

“Developers are looking beyond traditional amenities to offer services that make everyday life more convenient for residents,” said Drew Hopkins, President of Envoy Technologies. “On-site EV car sharing gives residents access to transportation without the commitment of owning another vehicle, while giving property owners more flexibility in how they approach mobility, parking and the overall residential experience.”

Montage at Midtown is the first phase of a broader $100 million redevelopment of Fort Myers’ Midtown district. The community features 321 apartments and a 17,000-square-foot amenity center, with future phases planned to include retail, office and additional residential development.

“Montage was designed to give residents the flexibility to live, work and get around without having to rely on a car for every trip,” said Cortney Mondon, Regional Manager at ZRS Management. “Having shared electric vehicles available right on the property gives our residents another convenient transportation option and complements the broader vision for Midtown as a connected, vibrant community.”

Through its “Mobility as an Amenity™” platform, Envoy manages the vehicles, charging, insurance, maintenance and resident support, while residents reserve and access the cars directly through the Envoy Mobility app. The fully managed service allows property partners to introduce EV car sharing without taking on day-to-day fleet operations.

Property managers and developers interested in bringing Envoy’s EV car-sharing amenity to their communities can learn more at envoythere.com/nominate.

About Envoy Technologies
Envoy provides on-site electric vehicle car-sharing services for residential communities, hotels, resorts and campus properties. Through the Envoy app, residents and guests can reserve shared electric vehicles by the hour or day, while Envoy manages insurance, maintenance and day-to-day operations. The service gives residents convenient access to electric transportation without the costs of individual vehicle ownership and offers property owners an additional amenity without the responsibility of managing vehicles.

Headquartered in Los Angeles, California, Envoy is a wholly owned subsidiary of Dot Ai (Nasdaq: DAIC).

For more information, visit https://www.envoythere.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, including statements regarding the anticipated benefits of the acquisition of Envoy, including, for example, the expected expansion of the Company’s intention to comply with the Hearing Panel’s condition to transfer its listing to The Nasdaq Capital Market; and the Company’s ability to maintain compliance with applicable Nasdaq listing requirements. All forward-looking statements are based on Dot Ai’s current expectations and beliefs concerning future developments and their potential effects on the Company. Forward-looking statements are subject to risks and uncertainties — including the risk that required stockholder, Nasdaq, or regulatory approvals may not be obtained, that the Company may be unable to regain or maintain compliance with applicable Nasdaq listing requirements — that could cause actual results to differ materially from those expressed in the forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and Dot Ai assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Important Information for Stockholders

In connection with the proposed transactions, the Company intends to file a proxy statement with the SEC. The Company also plans to file other documents with the SEC regarding the proposed transactions. After the proxy statement has been cleared by the SEC, a definitive proxy statement will be filed with the SEC and mailed to the stockholders of record of the Company. The Board will set the record date prior to mailing the definitive proxy statement. STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY READ THE PROXY STATEMENT (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE PROPOSED TRANSACTIONS THAT WILL BE FILED WITH THE SEC IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS. Stockholders will be able to obtain free copies of the proxy statement and other documents containing important information about the Company once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov.

Participants in the Solicitation

The Company and its executive officers, directors, other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of the Company is set forth in the Company’s definitive proxy statement for the Company’s 2026 annual meeting of stockholders filed with the SEC on April 17, 2026 and in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 11, 2026. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the proxy statement and other materials to be filed with the SEC in connection with the transactions contemplated by the Purchase Agreement.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

Media Contact
Marilyn Mota, Marketing Manager
press@envoythere.com

THE WOODLANDS, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced financial results for the third quarter and the nine months ended September 30, 2026.

“We delivered strong third quarter financial results, generating year-over-year growth in closings, revenue, and earnings while maintaining strong profitability, expanding our community count, and further strengthening our balance sheet,” said Eric Lipar, Chairman and Chief Executive Officer of LGI Homes.

“During the quarter, we delivered 1,222 homes, a 10.4% increase year-over-year, including 33 currently and previously leased homes. The 1,189 new homes we closed generated homebuilding revenues of $437.5 million, up 10.3%, and total revenues reached $444.5 million, up 10.2% from the prior year.

“Homebuilding gross margin of 20.2% and adjusted homebuilding gross margin of 23.7% were both above the midpoint of our previous guidance ranges and up 40 basis points sequentially. This reflects the continued benefits of our predominantly self-developed, on-balance-sheet land position and our disciplined approach to balancing affordability and profitability. Our teams also did an excellent job managing costs. SG&A expenses declined on an absolute-dollar basis, and SG&A as a percentage of total revenues improved 180 basis points year-over-year. As a result, net income increased to $24.6 million, or $1.05 per diluted share. We also continued to strengthen our balance sheet, reducing our net debt to capital ratio to 40.6%, a 420 basis point improvement year-over-year.

“Community growth remains an important element of our long-term strategy. We ended the quarter with 151 active communities, a 7.1% increase compared to the same time last year.

“Based on our year-to-date results and current market conditions, we are narrowing our full-year closings guidance and now expect to close between 4,600 and 4,800 homes in 2026. The revised outlook reflects slower sales activity in the quarter as affordability pressures continued to weigh on demand. We continue to see interest in homeownership and are leaning into our proven sales and marketing strategies to improve sales pace while maintaining our disciplined approach to balancing affordability and profitability. We are maintaining the remainder of our full-year 2026 guidance.”

Mr. Lipar concluded, “As we head into the final quarter of the year, our focus is on finishing 2026 strong. Affordability remains the key consideration for today’s buyers, and we have intentionally broadened our sales process to work with more prospective customers who may need additional time to qualify. With a growing community count, a strengthened balance sheet, and teams that continue to execute at a high level, we believe LGI Homes is well positioned to achieve our full-year objectives and carry that momentum into 2027.”

Third Quarter 2026 Results and Comparisons to Third Quarter 2025

• Homebuilding revenues of $437.5 million, an increase of 10.3%
• Total home closings of 1,222, including 33 currently and previously leased homes, an increase of 10.4%
• Home closings of 1,189, an increase of 11.6%
• Average sales price per home closed of $367,962, a decrease of 1.2%
• Homebuilding gross margin as a percentage of homebuilding revenues of 20.2%
• Adjusted homebuilding gross margin* as a percentage of homebuilding revenues of 23.7%
• Net income before income taxes of $33.3 million
• Net income of $24.6 million or $1.05 basic EPS and $1.05 diluted EPS

Nine Months Ended September 30, 2026 Results and Comparisons to Nine Months Ended September 30, 2025

• Homebuilding revenues of $1,258.8 million, an increase of 2.2%
• Total home closings of 3,578, including 143 currently and previously leased homes, an increase of 4.4%
• Home closings of 3,435, an increase of 1.5%
• Average sales price per home closed of $366,449, an increase of 0.7%
• Homebuilding gross margin as a percentage of homebuilding revenues of 19.7%
• Homebuilding gross margin excluding inventory impairment* as a percentage of homebuilding revenues of 20.1%
• Adjusted homebuilding gross margin* as a percentage of homebuilding revenues of 23.4%
• Net income before income taxes of $74.2 million
• Net income of $53.7 million or $2.31 basic EPS and $2.31 diluted EPS
• Adjusted net income* of $57.2 million, or $2.46 adjusted basic EPS and $2.46 adjusted diluted EPS

*		Please see “Non-GAAP Measures” for a reconciliation of Homebuilding Gross Margin Excluding Inventory Impairment (a non-GAAP measure) and Adjusted Homebuilding Gross Margin (a non-GAAP measure) to Homebuilding Gross Margin, and Adjusted Net Income (a non-GAAP measure) to Net Income, the most directly comparable GAAP measures, and for calculations of adjusted basic EPS and adjusted diluted EPS.

Balance Sheet Highlights

• Total liquidity of $447.7 million at September 30, 2026, including cash and cash equivalents of $69.4 million and $378.3 million of availability under the Company’s revolving credit facility
• Net debt to capital ratio* of 40.6% at September 30, 2026

*		Please see “Non-GAAP Measures” for a reconciliation of net debt to capital ratio (a non-GAAP measure) to debt to capital ratio, the most directly comparable GAAP measure.

Full Year 2026 Outlook

Subject to the caveats in the Forward-Looking Statements section of this press release and the assumptions noted below, the Company is narrowing its home closings outlook for the full year 2026 and reiterating its other outlook items for the full year 2026. Currently, the Company expects for full year 2026:

• Home closings between 4,600 and 4,800
• Active selling communities at the end of 2026 between 150 and 160
• Average sales price per home closed between $360,000 and $370,000
• Homebuilding gross margin as a percentage of homebuilding revenues between 19.0% and 21.0%, adjusted for estimated capitalized interest and estimated purchase accounting of approximately 3.5%, which results in adjusted homebuilding gross margin (non-GAAP) as a percentage of homebuilding revenues between 22.5% and 24.5%
• SG&A as a percentage of total revenues between 15.0% and 16.0%
• Effective tax rate of approximately 26.5%

This outlook assumes that general economic conditions, including input costs, materials, product and labor availability, interest rates and mortgage availability, in the remainder of 2026 are similar to those experienced to date in 2026 and that construction costs, availability of land and land development costs for the remainder of 2026 are consistent with the Company’s recent experience. In addition, this outlook assumes that governmental regulations relating to land development and home construction are similar to those currently in place and does not take into account any additional changes to U.S. trade policies, including the imposition of tariffs and duties on homebuilding products.

Earnings Conference Call

The Company will host a conference call via live webcast for investors and other interested parties beginning at 12:30 p.m. Eastern Time on Tuesday, November 3, 2026 (the “Earnings Call”).

Participants may access the live webcast by visiting the Investor Relations section of the Company’s website at https://investor.lgihomes.com.

An archive of the Earnings Call webcast will be available for replay on the Company’s website for one year from the date of the Earnings Call.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

Forward-Looking Statements

Any statements made in this press release or on the Earnings Call that are not statements of historical fact, including statements about the Company’s beliefs, outlook and expectations, are forward-looking statements within the meaning of the federal securities laws, and should be evaluated as such. Forward-looking statements include information concerning expected 2026 home closings, active selling communities, average sales price per home closed, homebuilding gross margin as a percentage of homebuilding revenues, adjusted homebuilding gross margin as a percentage of homebuilding revenues, SG&A as a percentage of total revenues and effective tax rate, as well as market conditions and possible or assumed future results of operations, including descriptions of the Company’s business plan and strategies. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “objective,” “plan,” “potential,” “predict,” “projection,” “should,” “will” or, in each case, their negative, or other variations or comparable terminology. For more information concerning factors that could cause actual results to differ materially from those contained in the forward-looking statements please refer to the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including the “Cautionary Statement about Forward-Looking Statements” subsection within the “Risk Factors” section, and subsequent filings by the Company with the U.S. Securities and Exchange Commission (the “SEC”), including the “Risk Factors” and “Cautionary Statement about Forward-Looking Statements” sections in the Company’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026 (when it is filed with the SEC). The Company bases these forward-looking statements or outlook on its current expectations, plans and assumptions that it has made in light of its experience in the industry, as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances and at such time. As you read and consider this press release or listen to the Earnings Call, you should understand that these statements are not guarantees of future performance or results. The forward-looking statements, including the Company’s 2026 outlook, are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or outlook. Although the Company believes that these forward-looking statements and outlook are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect the Company’s actual results to differ materially from those expressed in the forward-looking statements and outlook. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. If the Company does update one or more forward-looking statements, there should be no inference that it will make additional updates with respect to those or other forward-looking statements.

LGI HOMES, INC. CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except share data)
	September 30, 2026				December 31, 2025
ASSETS
Cash and cash equivalents	$	69,437			$	61,247
Accounts receivable		29,013				32,467
Real estate inventory		3,487,271				3,555,602
Pre-acquisition costs and deposits		22,420				28,950
Property and equipment, net		189,811				107,145
Other assets		115,996				119,909
Deferred tax assets, net		10,483				9,904
Goodwill		12,018				12,018
Total assets	$	3,936,449			$	3,927,242
LIABILITIES AND EQUITY
Accounts payable	$	67,381			$	16,179
Accrued expenses and other liabilities		164,176				157,971
Notes payable, net		1,544,466				1,656,803
Total liabilities		1,776,023				1,830,953
COMMITMENTS AND CONTINGENCIES
EQUITY
Common stock, par value $0.01, 250,000,000 shares authorized, 27,926,950 shares issued and 23,270,358 shares outstanding as of September 30, 2026 and 27,789,678 shares issued and 23,133,086 shares outstanding as of December 31, 2025		279				277
Additional paid-in capital		357,690				347,308
Retained earnings		2,212,039				2,158,339
Treasury stock, at cost, 4,656,592 shares as of September 30, 2026 and December 31, 2025		(409,582	)			(409,635	)
Total equity		2,160,426				2,096,289
Total liabilities and equity	$	3,936,449			$	3,927,242

LGI HOMES, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In thousands, except share and per share data)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Revenues
Homebuilding revenues	$	437,507			$	396,632			$	1,258,754			$	1,231,537
Land and other revenues		6,957				6,869				34,634				43,594
Total revenues		444,464				403,501				1,293,388				1,275,131
Cost of sales
Homebuilding costs		349,018				311,520				1,010,942				962,104
Land and other costs		6,262				4,712				30,437				37,441
Total cost of sales		355,280				316,232				1,041,379				999,545
Selling expenses		35,757				35,661				112,556				119,602
General and administrative		26,298				27,967				82,730				88,570
Other income, net		(6,180	)			(3,060	)			(17,496	)			(7,051	)
Net income before income taxes		33,309				26,701				74,219				74,465
Income tax provision		8,753				6,997				20,519				19,234
Net income	$	24,556			$	19,704			$	53,700			$	55,231
Earnings per share:
Basic	$	1.05			$	0.85			$	2.31			$	2.38
Diluted	$	1.05			$	0.85			$	2.31			$	2.37
Weighted average shares outstanding:
Basic		23,331,728				23,056,904				23,210,620				23,223,736
Diluted		23,466,066				23,149,005				23,281,055				23,289,280

Homebuilding Revenues, Home Closings, Average Sales Price Per Home Closed (ASP), Average Community Count, Average Monthly Absorption Rate, and Ending Community Count by Reportable Segment
(Revenues in thousands, unaudited)

		Three Months Ended September 30, 2026												As of September 30, 2026
Reportable Segment		Homebuilding Revenues			Home Closings		ASP			Average Community Count		Average Monthly Absorption Rate		Community Count at End of Period
Central		$	103,495		342		$	302,617		50.3		2.3		49
Southeast			109,238		335			326,084		30.0		3.7		30
Northwest			60,125		115			522,826		18.0		2.1		18
West			108,581		239			454,314		29.3		2.7		29
Florida			56,068		158			354,861		24.4		2.2		25
Total		$	437,507		1,189		$	367,962		152.0		2.6		151

		Three Months Ended September 30, 2025												As of September 30, 2025
Reportable Segment		Homebuilding Revenues			Home Closings		ASP			Average Community Count		Average Monthly Absorption Rate		Community Count at End of Period
Central		$	99,355		307		$	323,632		45.0		2.3		45
Southeast			101,419		299			339,194		32.3		3.1		32
Northwest			49,408		109			453,284		14.7		2.5		14
West			91,699		203			451,719		25.7		2.6		25
Florida			54,751		147			372,456		24.3		2.0		25
Total		$	396,632		1,065		$	372,424		142.0		2.5		141

Homebuilding Revenues, Home Closings, Average Sales Price Per Home Closed (ASP), Average Community Count, Average Monthly Absorption Rate, and Ending Community Count by Reportable Segment
(Revenues in thousands, unaudited)

		Nine Months Ended September 30, 2026												As of September 30, 2026
Reportable Segment		Homebuilding Revenues			Home Closings		ASP			Average Community Count		Average Monthly Absorption Rate		Community Count at End of Period
Central		$	320,432		1,057		$	303,152		49.1		2.4		49
Southeast			289,706		877			330,338		29.8		3.3		30
Northwest			156,736		302			518,993		16.4		2.0		18
West			319,040		710			449,352		28.2		2.8		29
Florida			172,840		489			353,456		23.9		2.3		25
Total		$	1,258,754		3,435		$	366,449		147.4		2.6		151

		Nine Months Ended September 30, 2025												As of September 30, 2025
Reportable Segment		Homebuilding Revenues			Home Closings		ASP			Average Community Count		Average Monthly Absorption Rate		Community Count at End of Period
Central		$	313,487		997		$	314,430		47.8		2.3		45
Southeast			353,211		1,067			331,032		31.8		3.7		32
Northwest			137,132		274			500,482		15.8		1.9		14
West			258,994		592			437,490		25.3		2.6		25
Florida			168,713		454			371,615		24.6		2.1		25
Total		$	1,231,537		3,384		$	363,929		145.3		2.6		141

Owned and Controlled Lots

The table below shows (i) home closings by reportable segment for the nine months ended September 30, 2026 and (ii) the Company’s owned or controlled lots by reportable segment as of September 30, 2026.

			Nine Months Ended September 30, 2026		As of September 30, 2026
Reportable Segment			Home Closings		Owned (1)		Controlled		Total
	Central		1,057		17,813		671		18,484
	Southeast		877		12,602		2,119		14,721
	Northwest		302		5,879		1,012		6,891
	West		710		8,947		3,111		12,058
	Florida		489		5,029		1,217		6,246
Total			3,435		50,270		8,130		58,400
(1)	Of the 50,270 owned lots as of September 30, 2026, 34,119 were raw/under development lots and 16,151 were finished lots. Finished lots included 2,147 completed homes, including information centers, and 1,626 homes in progress.

Backlog Data

As of the dates set forth below, the Company’s net orders, cancellation rate and ending backlog homes and value were as follows (dollars in thousands, unaudited):

		Nine Months Ended September 30,
Backlog Data		2026 (4)				2025 (5)
Net orders (1)			2,869				4,098
Cancellation rate (2)			48.9	%			28.1	%
Ending backlog – homes (3)			685				1,305
Ending backlog – value (3)		$	273,711			$	498,713
(1)	Net orders are new (gross) orders for the purchase of homes during the period, less cancellations of existing purchase contracts during the period.
(2)	Cancellation rate for a period is the total number of purchase contracts cancelled during the period divided by the total new (gross) orders for the purchase of homes during the period.
(3)	Ending backlog consists of retail homes at the end of the period that are under a purchase contract that has been signed by homebuyers who have met preliminary financing criteria but have not yet closed and wholesale contracts with varying terms. Ending backlog is valued at the contract amount.
(4)	As of September 30, 2026, the Company had 85 units related to bulk sales agreements associated with its wholesale business.
(5)	As of September 30, 2025, the Company had 60 units related to bulk sales agreements associated with its wholesale business.

Non-GAAP Measures

In addition to the results reported in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has provided information in this press release relating to adjusted net income, adjusted basic earnings per share, adjusted diluted earnings per share, homebuilding gross margin excluding inventory impairment, adjusted homebuilding gross margin, and net debt to capital ratio.

Adjusted Net Income, Adjusted Basic Earnings per Share, and Adjusted Diluted Earnings per Share

Adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share are non-GAAP financial measures used by management as supplemental measures in evaluating operating performance. The Company defines adjusted net income as net income less inventory impairment charges. The Company defines adjusted basic earnings per share as adjusted net income divided by weighted average basic shares outstanding. The Company defines adjusted diluted earnings per share as adjusted net income divided by weighted average diluted shares outstanding. Management believes that the presentation of adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share provides useful information to investors because such measures isolate the impact that inventory impairment charges have on net income and earnings per share. However, because adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share exclude the inventory impairment charge, which has real economic effects and could impact the Company’s results, the utility of adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share as measures of the Company’s operating performance may be limited. In addition, other companies may not calculate adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share in the same manner that the Company does. Accordingly, adjusted net income, adjusted basic earnings per share, and adjusted diluted earnings per share should be considered only as supplements to net income, basic earnings per share, and diluted earnings per share, respectively, as measures of the Company’s performance.

The following table reconciles adjusted net income to net income, which is the GAAP financial measure that management believes to be most directly comparable, and adjusted basic earnings per share and adjusted diluted earnings per share are calculated by dividing adjusted net income by basic or diluted weighted average shares outstanding, respectively (dollars in thousands, except earnings per share, unaudited):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Net income	$	24,556		$	19,704		$	53,700		$	55,231
Basic weighted average number of shares outstanding		23,331,728			23,056,904			23,210,620			23,223,736
Basic earnings per share	$	1.05		$	0.85		$	2.31		$	2.38
Diluted weighted average number of shares outstanding		23,466,066			23,149,005			23,281,055			23,289,280
Diluted earnings per share	$	1.05		$	0.85		$	2.31		$	2.37

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026				2025
Net income	$	24,556		$	19,704		$	53,700			$	55,231
Inventory impairment		—			—			4,681				—
Tax impact due to above reconciling item		—			—			(1,225	)			—
Adjusted net income	$	24,556		$	19,704		$	57,156			$	55,231
Basic weighted average number of shares outstanding		23,331,728			23,056,904			23,210,620				23,223,736
Adjusted basic earnings per share	$	1.05		$	0.85		$	2.46			$	2.38
Diluted weighted average number of shares outstanding		23,466,066			23,149,005			23,281,055				23,289,280
Adjusted diluted earnings per share	$	1.05		$	0.85		$	2.46			$	2.37

Homebuilding Gross Margin Excluding Inventory Impairment and Adjusted Homebuilding Gross Margin

Homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin are non-GAAP financial measures used by management as supplemental measures in evaluating operating performance. The Company defines homebuilding gross margin excluding inventory impairment as homebuilding gross margin less inventory impairment charges. The Company defines adjusted homebuilding gross margin as homebuilding gross margin excluding inventory impairment, less capitalized interest and adjustments resulting from the application of purchase accounting included in the cost of sales. Management believes homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin are useful because they isolate the impact that capitalized interest, purchase accounting adjustments, and inventory impairment (as applicable) have on homebuilding gross margin. However, because homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin exclude capitalized interest, purchase accounting adjustments, and inventory impairment (as applicable), which have real economic effects and could impact the Company’s results, the utility of homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin as measures of the Company’s operating performance may be limited. In addition, other companies may not calculate homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin in the same manner that the Company does. Accordingly, homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin should be considered only as supplements to homebuilding gross margin as a measure of the Company’s performance.

The following table reconciles homebuilding gross margin excluding inventory impairment and adjusted homebuilding gross margin to homebuilding gross margin (homebuilding revenues less homebuilding costs), which is the GAAP financial measure that management believes to be most directly comparable (dollars in thousands, unaudited):

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Homebuilding revenues		$	437,507			$	396,632			$	1,258,754			$	1,231,537
Homebuilding costs			349,018				311,520				1,010,942				962,104
Homebuilding gross margin		$	88,489			$	85,112			$	247,812			$	269,433
	Inventory impairment		—				—				4,681				—
Homebuilding gross margin excluding inventory impairment		$	88,489			$	85,112			$	252,493			$	269,433
	Capitalized interest amortized to cost of sales		14,723				11,004				41,171				31,107
	Purchase accounting adjustments (1)		449				999				1,382				2,850
Adjusted homebuilding gross margin		$	103,661			$	97,115			$	295,046			$	303,390
Homebuilding gross margin % (2)			20.2	%			21.5	%			19.7	%			21.9	%
Homebuilding gross margin % excluding inventory impairment (2)			20.2	%			21.5	%			20.1	%			21.9	%
Adjusted homebuilding gross margin % (2)			23.7	%			24.5	%			23.4	%			24.6	%
(1)	Adjustments result from the application of purchase accounting for acquisitions and represent the amount of the fair value step-up adjustments included in cost of sales for real estate inventory sold after the acquisition dates.
(2)	Calculated as a percentage of homebuilding revenues.

Net Debt to Capital Ratio

Net debt to capital ratio is a non-GAAP financial measure used by management as a supplemental measure in understanding the leverage employed in the Company’s operations and as an indicator of its ability to obtain financing. The Company defines net debt to capital ratio as net debt (which is total debt minus cash and cash equivalents) divided by net debt plus total equity. Management believes that the presentation of net debt to capital ratio provides useful information to investors regarding the Company’s financial leverage and its ability to meet long-term obligations. By excluding cash and cash equivalents from total debt, the ratio offers a clearer view of the Company’s capital structure and financial flexibility. Management uses this metric to monitor the Company’s capital efficiency and to evaluate the effectiveness of its capital management strategies over time. Other companies may define this measure differently and, as a result, the Company’s measure of net debt to capital ratio may not be directly comparable to the measures of other companies.

The following table reconciles net debt to capital ratio to debt to capital ratio, which is the GAAP financial measure that management believes to be most directly comparable (dollars in thousands, unaudited):

		September 30, 2026				December 31, 2025
Total debt (Notes payable)		$	1,544,466			$	1,656,803
Total equity			2,160,426				2,096,289
Total capital		$	3,704,892			$	3,753,092
Debt to capital ratio			41.7	%			44.1	%
Total debt (Notes payable)		$	1,544,466			$	1,656,803
	Less: Cash and cash equivalents		69,437				61,247
Net debt		$	1,475,029			$	1,595,556
Total equity			2,160,426				2,096,289
Total net capital		$	3,635,455			$	3,691,845
Net debt to capital ratio (1)			40.6	%			43.2	%
(1)	Net debt to capital ratio is calculated as net debt (which is total debt minus cash and cash equivalents) divided by net debt plus total equity.

CONTACT:	Joshua D. Fattor
	Executive Vice President of Finance and Capital Markets
	Head of Investor Relations
	(281) 210-2586
	investorrelations@lgihomes.com

SINGAPORE, Nov. 03, 2026 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, today announced that its AI-first customer engagement platform, EngageLab, has partnered with SKYWORTH Solar Co., Ltd. SKYWORTH Solar has deployed EngageLab AppPush within its international business operations to streamline communications for global channel distributors, project engineering teams and end users, reinforcing its ongoing global expansion.

Founded in 2020 as a subsidiary of Skyworth Group, SKYWORTH Solar specializes in residential and commercial photovoltaics, energy storage, charging, and smart energy operations. As the company accelerates its international footprint—operating via localized teams and an extensive distributor network across more than 40 countries—the need for a robust, global messaging infrastructure has become critical.

Overcoming Communication Fragmentation in Global Markets
For a company transitioning from hardware export to delivering comprehensive, end-to-end energy solutions, reliable communication is the backbone of operational efficiency. As SKYWORTH Solar entered diverse markets across Europe, Southeast Asia, the Middle East, and Africa, it faced a highly fragmented Android ecosystem.

By integrating the EngageLab AppPush solution, SKYWORTH Solar has unified its notification routing capabilities, overcoming the limitations of disparate device manufacturer channels. This integration ensures consistent, localized, and compliant data transmission during peak operational periods or critical policy rollouts.

Driving Efficiency Across Three Core Scenarios
With EngageLab AppPush, SKYWORTH Solar has successfully tailored its messaging strategies to meet the distinct needs of its diverse user base:

• Streamlining Distributor Operations: The platform enables SKYWORTH Solar to distribute targeted updates regarding new product launches, pricing policies, inventory, and order statuses. Messages are intelligently scheduled and adapted to each distributor’s local time zone and device language, ensuring seamless operational alignment.
• Empowering On-Site Engineering Teams: For field personnel, the app reliably delivers construction milestones, inspection tasks, and critical equipment alerts (such as inverter or battery anomalies). By integrating with major device manufacturer channels alongside standard routing options, EngageLab ensures these time-sensitive notifications reach teams even in challenging outdoor connectivity environments.
• Enhancing the End-User Experience: Property owners receive prompt, periodic updates on energy generation and grid yields, as well as immediate alerts for any equipment anomalies, ensuring transparency and trust.

“As we expand our renewable energy solutions globally, staying connected with our distributors and field engineers in real time is paramount,” said the Head of Global Operations at SKYWORTH Solar. “EngageLab’s AppPush provides the reliability and intelligent routing we need to keep our international operations running smoothly.”

As SKYWORTH Solar continues to scale its channel network, this advanced communication infrastructure will grow in tandem. EngageLab remains committed to leveraging its AI-first engagement capabilities to help SKYWORTH Solar maintain synchronized, reliable, and context-aware communications with its global stakeholders.

About EngageLab
EngageLab is an AI-first customer engagement platform that helps you build stronger customer relationships with AI agents, unified customer data, and reliable delivery across channels. EngageLab’s global customers include Dhgate, HelloRide, The Consejo Nacional Electoral (CNE) of Ecuador, J&T Cargo, Blurams and many more.
For more information, please contact: marketing@engagelab.com

About Aurora Mobile Limited
Founded in 2011, Aurora Mobile (NASDAQ: JG) is a leading provider of customer engagement and marketing technology services. The Company is dedicated to empowering global enterprises with stable, efficient, and intelligent customer interaction solutions. Leveraging its first-mover advantage in mobile messaging, Aurora Mobile has evolved into a comprehensive platform that integrates Omnichannel Engagement, AI-Driven Marketing, Advanced AI Customer Support, and Frictionless Identity Security. Through its flagship brand EngageLab and its robust AI infrastructure GPTBots.ai, the Company helps businesses achieve seamless customer reach, automate complex marketing journeys, and optimize service efficiency with AI agents, accelerating digital transformation for clients worldwide.

For more information, please visit: https://ir.aurora-mobile.com/
Media contact: marketing@aurora-mobile.com

Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as Aurora Mobile’s strategic and operational plans, contain forward-looking statements. Aurora Mobile may also make written or oral forward-looking statements in its reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Aurora Mobile’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Aurora Mobile’s strategies; Aurora Mobile’s future business development, financial condition and results of operations; Aurora Mobile’s ability to attract and retain customers; its ability to develop and effectively market data solutions, and penetrate the existing market for developer services; its ability to transition to the new advertising-driven SAAS business model; its ability to maintain or enhance its brand; the competition with current or future competitors; its ability to continue to gain access to mobile data in the future; the laws and regulations relating to data privacy and protection; general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and Aurora Mobile undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:
Aurora Mobile Limited
E-mail: ir@aurora-mobile.com

Christensen Advisory
Ms. Xiaoyan Su
E-mail: Xiaoyan.Su@christensencomms.com